Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
Multi-center,double blind randomized phase III placebo controlled study in 250 men with
histologically proven prostate cancer with out bone metastases who are beginning ADT therapy
and who will receive concomitant treatment with either oral Fosamax 70mg once weekly or
placebo for one year.These men will be treated and follow up for one year,during which time
changes in BMD, markers of bone resorption and formation will be monitored.All patients will
receive calcium and vitamin D through out the study.